# Helix Nanotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/helix-nanotechnologies

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.helixnano.com/
- Latest round: Series A (Apr 4, 2024)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2013 by co-founders Hannu Rajaniemi Ph.D. (CEO), Nikolai Eroshenko Ph.D., Geoffrey Siwo, and Carina Namih, Helix Nanotechnologies, Inc. operates as a provider of mRNA technologies, vaccines, and therapies to pharmaceutical companies and healthcare providers focusing on immune system enhancement and disease prevention. In April 2024, Helix Nanotechnologies, Inc. raised an undisclosed amount of Series A funding from Alumni Ventures Group.


The company’s core offerings include advanced mRNA therapeutics that target specific pathogens and diseases, alongside innovative vaccine solutions aimed at addressing public health challenges such as infectious diseases and potentially cancer. Helix Nanotechnologies, Inc. serves a diverse clientele that includes healthcare institutions, research organizations, and pharmaceutical companies across North America, Europe, and parts of Asia, with a focus on markets that prioritize advanced biotechnology solutions.


The company generates revenue primarily through direct partnerships with pharmaceutical companies and healthcare providers, where collaborative development agreements set the framework for project funding and profit-sharing.


Helix Nanotechnologies, Inc. plans to launch new mRNA therapeutics and vaccine solutions in the upcoming year, targeting release dates aligned with ongoing clinical trials. They aim to expand their market presence into Europe and parts of Asia by the end of 2025. The recent Series A funding raised in April 2024 from Alumni Ventures Group will support these initiatives, providing essential resources for product development and market entry strategies.

## Funding rounds

- Series A, Apr 4, 2024 — Alumni Ventures Group, LongeVC

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A